We have evaluated drug retention rate and predictive factors of drug survival for interleukin-1 inhibitors in systemic juvenile idiopathic arthritis. Our findings suggest an excellent overall drug retention rate for both anakinra and canakinumab that might be further augmented by paying attention to adverse events and employing these agents as first-line biologics in an early disease phase.
Gaggiano, C., Sota, J., Insalaco, A., Cimaz, R., Alessio, M., Cattalini, M., Gallizzi, R., Maggio, M., Lopalco, G., La Torre, F., Fabiani, C., Pardeo, M., Olivieri, A., Sfriso, P., Salvarani, C., Grosso, S., Bracaglia, C., De Benedetti, F., Rigante, D., Cantarini, L., Drug retention rate and predictive factors of drug survival for interleukin-1 inhibitors in systemic juvenile idiopathic arthritis., <<PEDIATRIC RHEUMATOLOGY ONLINE JOURNAL>>, 2019; 10th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID) (17 (Suppl 1)): 1-2. [doi:10.3389/fphar.2018.01526] [http://hdl.handle.net/10807/136251]
Drug retention rate and predictive factors of drug survival for interleukin-1 inhibitors in systemic juvenile idiopathic arthritis.
Rigante, Donato;
2019
Abstract
We have evaluated drug retention rate and predictive factors of drug survival for interleukin-1 inhibitors in systemic juvenile idiopathic arthritis. Our findings suggest an excellent overall drug retention rate for both anakinra and canakinumab that might be further augmented by paying attention to adverse events and employing these agents as first-line biologics in an early disease phase.
| File | Dimensione | Formato | |
|---|---|---|---|
|
fphar-09-01526.pdf
accesso aperto
Tipologia file ?:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
562.31 kB
Formato
Adobe PDF
|
562.31 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
